Catalyst Pharmaceutical
CPRX
135 hedge funds and large institutions have $222M invested in Catalyst Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 23 closing their positions.
10% more capital invested
Capital invested by funds: $202M → $222M (+$20.3M)
1.4% less ownership
Funds ownership: 65.63% → 64.23% (-1.4%)
5% less funds holding
Funds holding: 142 → 135 (-7)
20% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 50
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
26% less call options, than puts
Call options by funds: $233K | Put options by funds: $313K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.76M |
| 2 |
Goldman Sachs
New York
|
+$2.32M |
| 3 |
RA
Royce & Associates
New York
|
+$2.08M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.79M |
| 5 |
Millennium Management
New York
|
+$1.37M |
Top Sellers
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$9.01M |
| 2 |
Morgan Stanley
New York
|
-$8.78M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.41M |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$699K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
LPL Financial
San Diego,
California
| – | -$30K | -10,000 | Closed |
|
|
GT
152
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$7K | -2,414 | Closed |
|
|
PWM
153
Provident Wealth Management
Brentwood,
Tennessee
| – | -$4K | -1,250 | Closed |
|
|
PHK
154
Point72 Hong Kong
Hong Kong
| – | -$2K | -565 | Closed |
|
|
ASN
155
Advisory Services Network
Atlanta,
Georgia
| – | -$1K | -400 | Closed |
|
|
CHAM
156
Clear Harbor Asset Management
Stamford,
Connecticut
| – | -$446 | -150 | Closed |
|
|
PA
157
Parallel Advisors
San Francisco,
California
| – | +$7 | +2 | New |
|
CPRX Hedge Fund Activity: Q4 2020 in Review
135 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2020, worth a combined $222M — up 10% from $202M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CPRX and 18 opened new positions — a net loss of 5 holders — while 50 trimmed existing stakes and 40 added.
The largest buyer was Vanguard Group, adding an estimated $2.76M. The largest seller was Mangrove Partners, exiting entirely with an estimated $9.01M sold.
- 135 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2020, down from 142 in Q3 2020.
- Funds reported $222M of Catalyst Pharmaceutical stock for Q4 2020, up 10% quarter-over-quarter.
- 18 funds opened new Catalyst Pharmaceutical positions in Q4 2020 and 23 closed out, a net change of -5 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2020 was Vanguard Group, an estimated $2.76M added.
- The largest Catalyst Pharmaceutical seller in Q4 2020 was Mangrove Partners, an estimated $9.01M sold.
Based on aggregated 13F filings for Q4 2020.